AstraZeneca's Datroway Leads in Triple-Negative Breast Cancer Treatment at ESMO
TL;DR Summary
AstraZeneca and Gilead Sciences presented successful trial results for antibody-drug conjugates as new first-line treatments for metastatic triple-negative breast cancer, offering potential options after over a decade without new approvals for this aggressive cancer type.
- At ESMO, AstraZeneca and Gilead square off in triple-negative breast cancer statnews.com
- ESMO 2025 – Datroway and Trodelvy face off in triple-negative breast | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
- Drug groups unveil advances in treating most difficult breast cancers Financial Times
- ESMO: AZ, Daiichi's Datroway outshines Gilead's Trodelvy in first global TROP2 showdown Fierce Pharma
- AstraZeneca's Datroway extends survival in aggressive breast cancer Reuters
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
87%
268 → 35 words
Want the full story? Read the original article
Read on statnews.com